Dexcor0.5 mg

Dexcor 0.5 mg is indicated for a broad range of inflammatory, allergic, autoimmune, and endocrine conditions, including:

Allergic Conditions

• Severe or incapacitating allergic states unresponsive to conventional treatment, including asthma, drug hypersensitivity reactions, contact and atopic dermatitis, seasonal or perennial allergic rhinitis, and serum sickness

Collagen and Rheumatic Disorders

• Systemic lupus erythematosus, rheumatoid arthritis (including juvenile cases), acute gouty arthritis, ankylosing spondylitis, psoriatic arthritis, dermatomyositis, and polymyositis
• Short-term adjunctive therapy during acute rheumatic carditis flares

Dermatologic Disorders

• Bullous dermatitis herpetiformis, exfoliative erythroderma, pemphigus, mycosis fungoides, and severe erythema multiforme (Stevens-Johnson syndrome)

Endocrine Disorders

• Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, cancer-related hypercalcemia, and nonsuppurative thyroiditis

Gastrointestinal Disorders

• Regional enteritis (Crohn's disease) and ulcerative colitis during acute flares

Hematologic Disorders

• Autoimmune hemolytic anemia, congenital hypoplastic (Diamond-Blackfan) anemia, idiopathic thrombocytopenic purpura, and selected secondary thrombocytopenias

Oncologic Conditions

• Adjunctive management of leukemias and lymphomas

Neurological Conditions

• Acute exacerbations of multiple sclerosis
• Cerebral edema associated with brain tumors, craniotomy, or head injury

Ophthalmic Conditions

• Temporal arteritis, uveitis, and ocular inflammation unresponsive to topical steroids

Renal Disorders

• Inducing diuresis or remission of proteinuria in idiopathic nephrotic syndrome or lupus nephritis

Respiratory Disorders

• Symptomatic sarcoidosis, berylliosis, idiopathic eosinophilic pneumonia, and disseminated pulmonary tuberculosis (used alongside anti-tubercular therapy, never alone)

Other Uses

• Diagnostic testing of adrenocortical function (dexamethasone suppression test)
• Trichinosis with neurologic or myocardial involvement
• Tuberculous meningitis with subarachnoid block, given with antituberculous therapy

Always take this medicine under the supervision and prescription of a registered physician.

Dexamethasone is a synthetic fluorinated glucocorticoid. It binds to intracellular glucocorticoid receptors, modulating gene transcription to reduce the production of inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This action suppresses leukocyte migration to sites of injury, reverses increased capillary permeability, and broadly dampens both the innate and adaptive immune response.

Following intravenous administration, the sodium phosphate ester is rapidly hydrolyzed in the bloodstream to release active dexamethasone. Plasma elimination half-life is roughly 190 minutes (about 3 hours), but its biological half-life — the duration of measurable anti-inflammatory and HPA-axis suppressive effect — extends to 36–54 hours, allowing once- or twice-daily dosing for most indications despite the relatively short plasma clearance.

Because dexamethasone has minimal mineralocorticoid (sodium-retaining) activity compared with hydrocortisone, it is often preferred in patients where fluid retention or hypertension is a clinical concern, even at high anti-inflammatory doses.

The adverse effects listed below are mainly associated with prolonged systemic corticosteroid therapy rather than short-term or local use:

Dexamethasone falls under FDA Pregnancy Category C. Adequate and well-controlled studies in pregnant women are lacking, and corticosteroids should be used in pregnancy only when the potential benefit to the mother outweighs the potential risk to the fetus.

Dexamethasone passes into breast milk. Mothers receiving high systemic doses should be advised against breastfeeding, or the risks and benefits should be discussed with their physician before continuing breastfeeding.

General

The lowest effective dose should be used to control the condition being treated, and any dose reduction should be carried out gradually to avoid adrenal insufficiency or disease flare.

Cardio-Renal

Use with caution in patients with congestive heart failure, hypertension, or renal insufficiency, owing to the drug's effects on fluid and electrolyte balance.

Endocrine

Drug-induced secondary adrenocortical insufficiency can be minimized through gradual dose tapering rather than abrupt discontinuation, particularly after prolonged therapy.

Gastrointestinal

Use cautiously in patients with active or latent peptic ulcer disease, diverticulitis, recent intestinal anastomosis, or nonspecific ulcerative colitis, as corticosteroids may mask signs of perforation or increase perforation risk.

Musculoskeletal

Patients at increased risk of osteoporosis, such as postmenopausal women, should be carefully evaluated before starting long-term corticosteroid therapy.

Neuropsychiatric

High-dose corticosteroid therapy has been associated with acute myopathy, most often in patients with myasthenia gravis or those receiving concurrent neuromuscular blocking agents (such as pancuronium). Psychiatric effects ranging from insomnia, mood swings, and personality changes to severe depression or frank psychosis may occur.

Acute overdosage with Dexcor 0.5 mg is unlikely to cause life-threatening toxicity. Management is supportive and symptomatic, focused on monitoring and correcting fluid, electrolyte, and blood glucose disturbances. In cases of chronic excessive use, the dose should be tapered gradually rather than stopped suddenly, to avoid acute adrenal insufficiency.

• Tablet: Store in a cool, dry place, protected from light and moisture.
• Injection: Store below 30°C, protected from light. Do not freeze.

Keep all medicines out of the reach of children.

• Pediatric patients: Should be titrated to the lowest effective dose to minimize potential effects on growth, and growth and development should be monitored during prolonged therapy.
• Elderly patients: May be at higher risk of osteoporosis, hypertension, and glucose intolerance; monitor bone health and metabolic parameters during extended use.
• Diabetic patients: Blood glucose should be monitored closely, as corticosteroids can reduce glucose tolerance and increase insulin or antidiabetic medication requirements.
• Patients with renal or hepatic impairment: Use with caution and clinical monitoring, since these conditions may affect drug handling and increase sensitivity to corticosteroid effects.